The improvement effect of liver dysfanction and inhibitory effect of fibrosis marker by sitagliptin or repaglinide treatment for fatty liver(liver dysfunction) patients with type2 diabetes mellitus.
Not Applicable
Recruiting
- Conditions
- Diabetes Mellitus Liver dysfunction
- Registration Number
- JPRN-UMIN000012513
- Lead Sponsor
- Osaka Medical College Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who have renal dysfunction 2) Patients whose medicine or its dosage changed during the study duration if antihypertensive drug, antilipidemial drug or medicine which effects on other liver functions is used. 3) Patients who are considered inappropriate as a target patient by a physician-in-charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method AFIC score(Ferritin, IRI, Type4collagen 7s)
- Secondary Outcome Measures
Name Time Method diagnostic imaging, blood test , adiponecti, GLP-1(Active form), free fatty acid